Floatz logo

Opnurasib

Neoplasms, Lung

Novartis PharmaceuticalsSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Neoplasms, Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Rivoceranib
Fuzhou General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Opnurasib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
53 / 100
View asset →
KRAS G12CDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →